Tumorigenic consequences of ARID2 dysregulation are multifactorial: (1) Transcriptomic profiling reveals significant ARID2 downregulation in HCC tissues, where it physically interacts with E2F1 to attenuate RNA Polymerase II recruitment at cyclin D1 (CCND1) and cyclin E1 (CCNE1) promoters. The gene discussed is CCNE1; the disease is hepatocellular carcinoma.